Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial
R Adams, E Brown, L Brown, R Butler, S Falk, D Fisher, R Kaplan, P Quirke, S Richman, L Samuel, J Seligmann, M Seymour, KK Shiu, H Wasan, Richard Wilson, T Maughan, FOCUS4 Trial Investigators
Dive into the research topics of 'Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial'. Together they form a unique fingerprint.